简化与协调癌症临床试验的新方法——标准化入组标准
LUNGevity基金会工作组联合临床医生、药企、美国国家癌症研究所、FDA和欧洲药品管理局代表,制定了一套用于一线晚期非小细胞肺癌临床试验的优先入组标准条目库,涵盖疾病分期与组织学特征、入组生物标志物、体能状态、器官功能、脑转移和合并症,旨在简化入组标准、便于利益相关方检索合适试验并协调试验人群以支持跨试验比较,该工作构成FDA即将发布的行业指南草案的基础。
要点
- 工作组生成了优先条目库,用于指导申办方设计一线晚期非小细胞肺癌注册性临床试验的入组标准。
- 推荐条目涵盖疾病分期与组织学特征、入组生物标志物、体能状态、器官功能、脑转移和合并症。
- 该工作构成FDA即将发布的行业指南草案的基础,并作为其他癌症类似工作的原型。
核心结论
- 作为初步步骤,推荐的跨试验入组标准标准化可能协调试验人群。
- 通过连接不同利益相关方并提供正式公众意见机会,新兴的FDA指南草案还可能为修订和简化长期存在的试验入组方法提供机会。
- 这项工作作为目前正在开展的其他癌症类似工作的原型。
研究设计与样本
- LUNGevity基金会工作组制定了肺癌临床试验入组标准框架。
- 临床医生与制药行业、美国国家癌症研究所、美国食品药品监督管理局(FDA)、欧洲药品管理局和LUNGevity基金会的代表共同参与,识别并优先排序入组标准的关键条目。
- 工作组生成了优先条目库,用于指导研究者与申办方设计一线晚期非小细胞肺癌临床试验,该试验旨在支持上市申请。
主要发现
- 复杂且常过于严格的入组和排除标准对患者获取新疗法造成了实质性障碍,阻碍了试验招募和完成,并限制了试验结果的普遍性。
- 推荐条目涉及疾病分期与组织学特征、入组生物标志物、体能状态、器官功能、脑转移和合并症。
关键数值与推荐
- 推荐条目涵盖疾病分期与组织学特征、入组生物标志物、体能状态、器官功能、脑转移和合并症。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: Clinical trial sponsors rely on eligibility criteria to control the characteristics of patients in their studies, promote the safety of participants, and optimize the interpretation of results. However, in recent years, complex and often overly restrictive inclusion and exclusion criteria have created substantial barriers to patient access to novel therapies, hindered trial recruitment and completion, and limited generalizability of trial results. A LUNGevity Foundation working group developed a framework for lung cancer clinical trial eligibility criteria. The goals of this framework are to (1) simplify eligibility criteria, (2) facilitate stakeholders' (patients, clinicians, and sponsors) search for appropriate trials, and (3) harmonize trial populations to support intertrial comparisons of treatment effects. OBSERVATIONS: Clinicians and representatives from the pharmaceutical industry, the National Cancer Institute, the US Food and Drug Administration (FDA), the European Medicines Agency, and the LUNGevity Foundation undertook a process to identify and prioritize key items for inclusion in trial eligibility criteria. The group generated a prioritized library of terms to guide investigators and sponsors in the design of first-line, advanced non-small cell lung cancer clinical trials intended to support marketing application. These recommendations address disease stage and histologic features, enrollment biomarkers, performance status, organ function, brain metastases, and comorbidities. This effort forms the basis for a forthcoming FDA draft guidance for industry. CONCLUSIONS AND RELEVANCE: As an initial step, the recommended cross-trial standardization of eligibility criteria may harmonize trial populations. Going forward, by connecting diverse stakeholders and providing formal opportunity for public input, the emerging FDA draft guidance may also provide an opportunity to revise and simplify long-standing approaches to trial eligibility. This work serves as a prototype for similar efforts now underway for other cancers.
引用
- Gerber DE, Singh H, Larkins E, et al. A New Approach to Simplifying and Harmonizing Cancer Clinical Trials-Standardizing Eligibility Criteria. JAMA Oncol. 2022. PMID: 35925576. doi:10.1001/jamaoncol.2022.1664
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。